Ownership and insider activity for Adial Pharmaceuticals, Inc. (ADIL): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Adial Pharmaceuticals, Inc. is a biopharmaceutical enterprise operating at the clinical stage, dedicated to researching and developing innovative therapeutic options for the management and prevention of addiction and associated disorders. Its primary investigational compound, AD04, functions as a selective serotonin-3 antagonist and is currently undergoing pivotal Phase III clinical trials for the treatment of alcohol use disorder.
Price
| Price | $5.24 |
| Market Cap | $5M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-07-16 | Coastlands Capital LP | P-Purchase | 1,233 | $3K |
| 2026-07-14 | Coastlands Capital LP | P-Purchase | 2,000 | $5K |
| 2026-07-10 | Coastlands Capital LP | P-Purchase | 1,700 | $5K |
| 2026-07-09 | Coastlands Capital LP | P-Purchase | 10,053 | $28K |
| 2026-06-29 | Coastlands Capital LP | P-Purchase | 25,000 | $65K |
| 2026-06-24 | Coastlands Capital LP | |||
| 2026-06-24 | Coastlands Capital LP | 3,637,818 | $4K | |
| 2026-06-12 | Davidson Matt | A-Award | 232,417 | |
| 2026-06-12 | Davidson Matt | A-Award | 232,417 | $672K |
| 2026-06-11 | Davidson Matt | A-Award | 61,647 |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $87993 | $18248 | $3.9M | $6.8M | $4.4M | $6.1M | $4.0M | $2.8M | $3.8M | $5.9M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | $35117 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $41758 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $141413 | $27248 | $4.7M | $7.7M | $5.1M | $6.5M | $4.8M | $3.2M | $4.1M | $6.2M |
| Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 | $304358 | $244421 | $3909 | 0 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | $248971 | 0 | 0 | 0 | 0 |
| Intangible Assets | $7863 | $7298 | $6735 | $6170 | $5606 | $5041 | $4477 | $3913 | $3348 | $2784 |
| Total Assets | $151526 | $34546 | $4.7M | $7.7M | $5.5M | $7.6M | $5.7M | $4.7M | $5.0M | $6.8M |
| Accounts Payable | $20012 | $342082 | $99671 | $190204 | $648739 | $286192 | $276410 | $103325 | $250130 | $655207 |
| Short-term Debt | $234255 | $689265 | 0 | 0 | 0 | $49585 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $255019 | $1.0M | $257974 | $539051 | $1.5M | $2.7M | $1.8M | $653076 | $975858 | $1.4M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $255019 | $1.0M | $257974 | $539051 | $1.5M | $4.1M | $2.5M | $653513 | $975858 | $1.5M |
| Retained Earnings | -$9.9M | -$403992 | -$12.0M | -$20.6M | -$31.5M | -$50.9M | -$63.7M | -$68.8M | -$82.0M | -$90.0M |
| Total Equity | -$103493 | -$997553 | $4.4M | $7.1M | $4.0M | $3.5M | $3.3M | $4.1M | $4.1M | $5.3M |
| Total Debt | $234255 | $689265 | 0 | 0 | 0 | $256960 | $207375 | 0 | 0 | 0 |
| Net Debt | $146262 | $671017 | -$3.9M | -$6.8M | -$4.4M | -$5.8M | -$3.8M | -$2.8M | -$3.8M | -$5.9M |
| Working Capital | -$113606 | -$1.0M | $4.4M | $7.1M | $3.6M | $3.7M | $3.0M | $2.5M | $3.1M | $4.8M |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 5.63 |
| Piotroski F-Score | 4 |
| Altman Z-Score | -20.02 |
Profitability
| Return on Equity | -1693.21% |
| Return on Invested Capital | -240.64% |
| Return on Assets | -198.70% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ACXP · APRE · BCDA · BCLI · CDIO · CELZ · HCWB
Explore sector: Healthcare · Biotechnology
More sections of ADIL: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks